Alector’s consensus price target and future P/E multiple have both declined significantly, indicating more cautious growth expectations, resulting in a lower fair value estimate of $3.83.
What's in the News
- Alector updated its 2025 collaboration revenue guidance to between $13 million and $18 million.
- CFO Marc Grasso, M.D., will depart, with Chief Business Officer Neil Berkley, M.B.A., assuming the role of Interim CFO.
- Topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN is expected in Q4 2025; enrollment completed in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease in April 2025.
- The company continues to advance preclinical programs through its Alector Brain Carrier (ABC) platform, including ADP037-ABC for Alzheimer’s and ADP050-ABC for Parkinson’s disease.
- Alector was added to multiple Russell value and small-cap indices, including the Russell 2000 Value, 2500 Value, 3000 Value, Microcap Value, and Small Cap Comp Value Benchmarks.
Valuation Changes
Summary of Valuation Changes for Alector
- The Consensus Analyst Price Target has significantly fallen from $4.51 to $3.83.
- The Future P/E for Alector has significantly fallen from 8.97x to 7.63x.
- The Discount Rate for Alector remained effectively unchanged, moving only marginally from 6.91% to 6.90%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.